Skip to main content
Top
Published in: Drug Safety 10/2002

01-08-2002 | Review Article

Drug Interactions with Tacrolimus

Author: Dr Teun van Gelder

Published in: Drug Safety | Issue 10/2002

Login to get access

Abstract

Tacrolimus is a drug for which therapeutic drug monitoring is recommended. The existence of a wide variety of potential drug interactions further supports the current strategy of measuring whole blood tacrolimus concentrations in transplanted patients.
Cytochrome P450 (CYP)3A, the major phase I metabolising enzyme in humans, and the multi-drug efflux pump, P-glycoprotein, are present at high levels in the villus tip of enterocytes in the gastrointestinal tract. Oral bioavailability of tacrolimus can be increased by concomitant administration of inhibitors of either CYP3A or P-glycoprotein. CYP activity in the liver also influences tacrolimus concentrations. As a result, several drugs that are frequently being used in transplantation, such as corticosteroids and antifungal agents, will affect tacrolimus concentrations. Knowledge of such drug interactions is extremely important, as they may lead to clinically important under- or overexposure to tacrolimus, with acute rejection episodes or serious toxicity as a result.
Literature
1.
go back to reference Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Drug Saf 1995; 12: 348–57PubMedCrossRef Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Drug Saf 1995; 12: 348–57PubMedCrossRef
2.
go back to reference Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK506). Ther Drug Monit 1995; 17: 606–14PubMedCrossRef Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK506). Ther Drug Monit 1995; 17: 606–14PubMedCrossRef
3.
go back to reference Krahenbuhl S, Menafoglio A, Giostra E, et al. Serious interaction between mibefadril and tacrolimus. Transplantation 1998; 66: 1113–5PubMedCrossRef Krahenbuhl S, Menafoglio A, Giostra E, et al. Serious interaction between mibefadril and tacrolimus. Transplantation 1998; 66: 1113–5PubMedCrossRef
4.
go back to reference Chenhsu RY, Loong CC, Chou MH, et al. Renal allograft dysfunction associated with rifampicin-tacrolimus interaction. Ann Pharmacotherapy 2000; 34: 27–31CrossRef Chenhsu RY, Loong CC, Chou MH, et al. Renal allograft dysfunction associated with rifampicin-tacrolimus interaction. Ann Pharmacotherapy 2000; 34: 27–31CrossRef
5.
go back to reference Moreno M, Latorre A, Manzanares C, et al. Clinical management of tacrolimus drug interactions in renal transplant patients. Transpl Proc 1999; 31: 2252–3CrossRef Moreno M, Latorre A, Manzanares C, et al. Clinical management of tacrolimus drug interactions in renal transplant patients. Transpl Proc 1999; 31: 2252–3CrossRef
6.
go back to reference Brazelton TR, Morris RE. Molecular mechanisms of action of newxenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996; 8: 710–20PubMedCrossRef Brazelton TR, Morris RE. Molecular mechanisms of action of newxenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996; 8: 710–20PubMedCrossRef
7.
go back to reference Kung L, Gourishankar S, Halloran PF. Molecular pharmacology of immunosuppressive agents in relation to their clinical use. Curr Opin Organ Transplant 2000; 5: 268–75CrossRef Kung L, Gourishankar S, Halloran PF. Molecular pharmacology of immunosuppressive agents in relation to their clinical use. Curr Opin Organ Transplant 2000; 5: 268–75CrossRef
8.
go back to reference Spencer CM, Goa KL, Gillis JC. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54: 925–75PubMedCrossRef Spencer CM, Goa KL, Gillis JC. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54: 925–75PubMedCrossRef
9.
go back to reference Sewing KF. Pharmacokinetics, dosing principles, and blood level monitoring of FK506. Transplant Proc 1994; 26: 3267–9PubMed Sewing KF. Pharmacokinetics, dosing principles, and blood level monitoring of FK506. Transplant Proc 1994; 26: 3267–9PubMed
10.
go back to reference Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinetic 1995; 29: 404–30CrossRef Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinetic 1995; 29: 404–30CrossRef
11.
go back to reference Bekersky I, Dressler D, Mekki QA. Effect of low-and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol 2001; 41: 176–82PubMedCrossRef Bekersky I, Dressler D, Mekki QA. Effect of low-and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol 2001; 41: 176–82PubMedCrossRef
12.
go back to reference Christiaans M, van Duijnhoven E, Beysens T, et al. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times post-transplant in renal transplant recipients. Transplant Proc 1998; 30: 1271–3PubMedCrossRef Christiaans M, van Duijnhoven E, Beysens T, et al. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times post-transplant in renal transplant recipients. Transplant Proc 1998; 30: 1271–3PubMedCrossRef
13.
go back to reference Bekersky I, Dressler D, Alak A, et al. Comparative tacrolimus pharmacokinetics: normal versusmildly hepatically impaired subjects. J Clin Pharmacol 2001; 41: 628–35PubMedCrossRef Bekersky I, Dressler D, Alak A, et al. Comparative tacrolimus pharmacokinetics: normal versusmildly hepatically impaired subjects. J Clin Pharmacol 2001; 41: 628–35PubMedCrossRef
14.
go back to reference Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 2001; 40: 283–95PubMedCrossRef Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 2001; 40: 283–95PubMedCrossRef
15.
go back to reference Garcia Sanchez MJ, Manzanares C, Santos-Buelga D, et al. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinetic 2001; 40: 63–71CrossRef Garcia Sanchez MJ, Manzanares C, Santos-Buelga D, et al. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinetic 2001; 40: 63–71CrossRef
16.
go back to reference Sheiner PA, Mor E, Chodoff L, et al. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. Transplantation 1993; 57: 1132–3 Sheiner PA, Mor E, Chodoff L, et al. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. Transplantation 1993; 57: 1132–3
17.
go back to reference Lake KD, Canafax DM. Important interactions of drugs with immunosuppressive agents used in transplant recipients. J Antimicrob Chemother 1995; 36Suppl. B: 11–22PubMedCrossRef Lake KD, Canafax DM. Important interactions of drugs with immunosuppressive agents used in transplant recipients. J Antimicrob Chemother 1995; 36Suppl. B: 11–22PubMedCrossRef
18.
go back to reference Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 2001; 41: 289–97PubMedCrossRef Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 2001; 41: 289–97PubMedCrossRef
19.
go back to reference Fleckenstein JF, Paredes M, Thuluvath PJ. A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxicholic acid in prevention of liver transplant rejection. Liver Transpl Surg 1998; 4: 276–9PubMedCrossRef Fleckenstein JF, Paredes M, Thuluvath PJ. A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxicholic acid in prevention of liver transplant rejection. Liver Transpl Surg 1998; 4: 276–9PubMedCrossRef
20.
go back to reference Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and p-glycoprotein. Clin Pharmacokinet 2001; 40: 159–68PubMedCrossRef Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and p-glycoprotein. Clin Pharmacokinet 2001; 40: 159–68PubMedCrossRef
21.
go back to reference Fricker G, Miller DS. Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo. Pharmacol Toxicol 2002; 90: 5–13PubMedCrossRef Fricker G, Miller DS. Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo. Pharmacol Toxicol 2002; 90: 5–13PubMedCrossRef
22.
go back to reference Von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphismor a CYP3A4 promotor polymorphisms (CYP3A4-V allele) on dose-adjusted cyclosporine A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048–52 Von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphismor a CYP3A4 promotor polymorphisms (CYP3A4-V allele) on dose-adjusted cyclosporine A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048–52
23.
go back to reference Piekoszewski W, Jusko WJ. Plasma protein binding of tacrolimus in humans. J Pharm Sci 1993; 82: 340–1PubMedCrossRef Piekoszewski W, Jusko WJ. Plasma protein binding of tacrolimus in humans. J Pharm Sci 1993; 82: 340–1PubMedCrossRef
24.
go back to reference Nagase K, Iwasaki K, Nozaki K, et al. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol 1994; 46: 113–7PubMedCrossRef Nagase K, Iwasaki K, Nozaki K, et al. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol 1994; 46: 113–7PubMedCrossRef
25.
go back to reference Iwasaki K, Shiraga T, Matsuda H, et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos 1995; 23: 28–34PubMed Iwasaki K, Shiraga T, Matsuda H, et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos 1995; 23: 28–34PubMed
26.
go back to reference Alak AM, Moy S. Biological activity of tacrolimus (FK506) and its main metabolites from whole blood of kidney transplant recipients. Transplant Proc 1997; 29: 2487–90PubMedCrossRef Alak AM, Moy S. Biological activity of tacrolimus (FK506) and its main metabolites from whole blood of kidney transplant recipients. Transplant Proc 1997; 29: 2487–90PubMedCrossRef
27.
go back to reference Christians U, Schmidt G, Guengerich FP, et al. In vitro metabolism of FK506, cytochrome P450 and drug interactions. Ther Drug Monit 1993; 15: 145CrossRef Christians U, Schmidt G, Guengerich FP, et al. In vitro metabolism of FK506, cytochrome P450 and drug interactions. Ther Drug Monit 1993; 15: 145CrossRef
28.
go back to reference Christians U, Schmidt G, Bader A, et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 1996; 41: 187–90PubMedCrossRef Christians U, Schmidt G, Bader A, et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 1996; 41: 187–90PubMedCrossRef
29.
go back to reference Hebert MF, Fisher RM, Marsh CL, et al. Effects of rifampicin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39: 91–6PubMedCrossRef Hebert MF, Fisher RM, Marsh CL, et al. Effects of rifampicin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39: 91–6PubMedCrossRef
30.
go back to reference Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John’s wort. Lancet 2000; 355: 548–9PubMedCrossRef Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John’s wort. Lancet 2000; 355: 548–9PubMedCrossRef
31.
go back to reference Smak Gregoor PJH, van Gelder T, van der Ende ME, et al. Cyclosporine and triple-drug treatment with human immunodeficiency virus protease inhibitors. Transplantation 1999; 68: 1210–1CrossRef Smak Gregoor PJH, van Gelder T, van der Ende ME, et al. Cyclosporine and triple-drug treatment with human immunodeficiency virus protease inhibitors. Transplantation 1999; 68: 1210–1CrossRef
32.
go back to reference Sheikh AM, Wolf DC, Lebovics E, et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 1999; 68: 307–9PubMedCrossRef Sheikh AM, Wolf DC, Lebovics E, et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 1999; 68: 307–9PubMedCrossRef
33.
go back to reference Schwrcz R, Rudbeck G, Soderdahl G, et al. Interaction between nelfinavir and tacrolimus after orthotopic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation 2000; 69: 2194–5CrossRef Schwrcz R, Rudbeck G, Soderdahl G, et al. Interaction between nelfinavir and tacrolimus after orthotopic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation 2000; 69: 2194–5CrossRef
34.
go back to reference Keay S, Oldach D, Redfield R, et al. Organ transplantation in the HIV-infected patient. Curr Opin Organ Transpl 2000; 5: 217–23CrossRef Keay S, Oldach D, Redfield R, et al. Organ transplantation in the HIV-infected patient. Curr Opin Organ Transpl 2000; 5: 217–23CrossRef
35.
go back to reference Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and p-glycoprotein. Clin Pharmacol Ther 1999; 65: 237–44PubMedCrossRef Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and p-glycoprotein. Clin Pharmacol Ther 1999; 65: 237–44PubMedCrossRef
36.
37.
go back to reference Michelangelo V, Piero D, Elisa C, et al. Grapefruit juice and kinetics of tacrolimus [abstract]. J Am Soc Nephrol 2001; 12: 862A Michelangelo V, Piero D, Elisa C, et al. Grapefruit juice and kinetics of tacrolimus [abstract]. J Am Soc Nephrol 2001; 12: 862A
38.
go back to reference Undre NA, Schafer A, and the European Tacrolimus Multicentre Renal Study Group. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. Transplant Proc 1998; 30: 1261–3PubMedCrossRef Undre NA, Schafer A, and the European Tacrolimus Multicentre Renal Study Group. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. Transplant Proc 1998; 30: 1261–3PubMedCrossRef
39.
go back to reference Albengres E, LeLouet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998; 18(2): 83–97PubMedCrossRef Albengres E, LeLouet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998; 18(2): 83–97PubMedCrossRef
40.
go back to reference Mignat C. Clinically significant drug interactions with new immunosuppressive drugs. Drug Saf 1997; 16(4): 267–78PubMedCrossRef Mignat C. Clinically significant drug interactions with new immunosuppressive drugs. Drug Saf 1997; 16(4): 267–78PubMedCrossRef
41.
go back to reference Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997; 5: 225–32PubMedCrossRef Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997; 5: 225–32PubMedCrossRef
42.
go back to reference Smak Gregoor PJH, Van Gelder T, Hesse CJ, et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant 1999; 14(3): 706–8PubMedCrossRef Smak Gregoor PJH, Van Gelder T, Hesse CJ, et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant 1999; 14(3): 706–8PubMedCrossRef
43.
go back to reference Smak Gregoor PJH, De Sévaux RGL, Henè RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999; 68(10): 1603–6CrossRef Smak Gregoor PJH, De Sévaux RGL, Henè RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999; 68(10): 1603–6CrossRef
44.
go back to reference Van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119–28PubMedCrossRef Van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119–28PubMedCrossRef
45.
go back to reference Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000; 14: 100–4PubMedCrossRef Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000; 14: 100–4PubMedCrossRef
46.
go back to reference Pirsch J, Bekersky I, Vincenti F, et al. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharm 2000; 40: 527–32CrossRef Pirsch J, Bekersky I, Vincenti F, et al. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharm 2000; 40: 527–32CrossRef
47.
go back to reference Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1–34PubMedCrossRef Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1–34PubMedCrossRef
48.
go back to reference Mück W, Neal DAJ, Boix O, et al. Tacrolimus/cerivastatin interaction study in liver transplant recipients. Brit J Clin Pharmacol 2001; 52: 213–7CrossRef Mück W, Neal DAJ, Boix O, et al. Tacrolimus/cerivastatin interaction study in liver transplant recipients. Brit J Clin Pharmacol 2001; 52: 213–7CrossRef
49.
go back to reference Penson MG, Fricker FJ, Thompson JR, et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 2001; 20: 611–8PubMedCrossRef Penson MG, Fricker FJ, Thompson JR, et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 2001; 20: 611–8PubMedCrossRef
50.
go back to reference Manzanares C, Moreno M, Castellanos F, et al. Influence of hepatitis C virus infection on FK506 blood levels in renal transplant patients. Transplant Proc 1998; 30: 1264–5PubMedCrossRef Manzanares C, Moreno M, Castellanos F, et al. Influence of hepatitis C virus infection on FK506 blood levels in renal transplant patients. Transplant Proc 1998; 30: 1264–5PubMedCrossRef
51.
go back to reference Armstrong V, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus and azathioprine. Clin Biochem 2001; 34: 9–16PubMedCrossRef Armstrong V, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus and azathioprine. Clin Biochem 2001; 34: 9–16PubMedCrossRef
Metadata
Title
Drug Interactions with Tacrolimus
Author
Dr Teun van Gelder
Publication date
01-08-2002
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 10/2002
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200225100-00003

Other articles of this Issue 10/2002

Drug Safety 10/2002 Go to the issue